BMAPN explained

BMAPN (βk-methamnetamine) is a substituted cathinone derivative with stimulant effects. It inhibits dopamine reuptake and has rewarding and reinforcing properties in animal studies.^{[1] [2]} It is banned under drug analogue legislation in a number of jurisdictions. The drug was at one point marketed under the name NRG-3, although only a minority of samples of substances sold under this name have been found to actually contain BMAPN, with most such samples containing mixtures of other cathinone derivatives.^{[3] [4]}

See also

• βk-Ephenidine
• Methamnetamine
• Methylnaphthidate
• Methylone
• Naphyrone
• WF-23

Notes and References

1. Botanas CJ, Yoon SS, de la Peña JB, Dela Peña IJ, Kim M, Woo T, Seo JW, Jang CG, Park KT, Lee YH, Lee YS, Kim HJ, Cheong JH . A novel synthetic cathinone, 2-(methylamino)-1-(naphthalen-2-yl) propan-1-one (BMAPN), produced rewarding effects and altered striatal dopamine-related gene expression in mice . Behavioural Brain Research . 317 . 494–501 . January 2017 . 27737791 . 10.1016/j.bbr.2016.10.016 . 3095092 .
2. Book: Simmons SJ, Kim E, Gentile TA, Murad A, Muschamp JW, Rawls SM . 2018 . Behavioral Profiles and Underlying Transmitters/Circuits of Cathinone-Derived Psychostimulant Drugs of Abuse. . Zawilska J . Synthetic Cathinones . Current Topics in Neurotoxicity . 12 . 125–152 . Springer . Cham . 10.1007/978-3-319-78707-7_8. 978-3-319-78706-0 .
3. Brandt SD, Freeman S, Sumnall HR, Measham F, Cole J . Analysis of NRG 'legal highs' in the UK: identification and formation of novel cathinones . Drug Testing and Analysis . 3 . 9 . 569–75 . September 2011 . 21960541 . 10.1002/dta.204 .
4. Eiden C, Mathieu O, Cathala P, Debruyne D, Baccino E, Petit P, Peyriere H . Toxicity and death following recreational use of 2-pyrrolidino valerophenone . Clinical Toxicology . Philadelphia, Pa. . 51 . 9 . 899–903 . November 2013 . 24111554 . 10.3109/15563650.2013.847187 . 22826544 .